{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:26:10Z","timestamp":1791462370582,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["211754Pj01H"],"award-info":[{"award-number":["211754Pj01H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Mrs Berta Kamprad foundation for exploration and combat cancer","doi-asserted-by":"publisher","award":["FBKS-2020-13-293"],"award-info":[{"award-number":["FBKS-2020-13-293"]}],"id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","physicamedica.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physica Medica"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmp.2023.103166","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T02:42:31Z","timestamp":1699065751000},"page":"103166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy \u2013 Molecular radiotherapy"],"prefix":"10.1016","volume":"116","author":[{"given":"Katarina","family":"Sj\u00f6green-Gleisner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4743-2276","authenticated-orcid":false,"given":"Glenn","family":"Flux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0634-013X","authenticated-orcid":false,"given":"Carlo","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"de Nijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6983-2863","authenticated-orcid":false,"given":"George C.","family":"Kagadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lyra","family":"Georgosopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Minguez","family":"Gabi\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Nekolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0752-7134","authenticated-orcid":false,"given":"Steffie","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-9635","authenticated-orcid":false,"given":"Caroline","family":"Stokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9552-7750","authenticated-orcid":false,"given":"Johannes","family":"Tran-Gia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-4428","authenticated-orcid":false,"given":"Paddy","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1766-727X","authenticated-orcid":false,"given":"Manuel","family":"Bardi\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejmp.2023.103166_b0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0001-2998(79)80041-0","article-title":"Radionuclide therapy of hematologic disorders","volume":"9","author":"Silberstein","year":"1979","journal-title":"Semin Nucl Med"},{"issue":"9","key":"10.1016\/j.ejmp.2023.103166_b0010","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejmp.2023.103166_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2023.102620","article-title":"EFOMP Malaga Declaration 2023: An updated vision on Medical Physics in Europe","volume":"111","author":"Byrne","year":"2023","journal-title":"Phys Med"},{"key":"10.1016\/j.ejmp.2023.103166_b0020","unstructured":"Council Directive 2013\/59\/Euratom,. Official Journal of the European Union, 20157."},{"issue":"2\u20134","key":"10.1016\/j.ejmp.2023.103166_b0025","first-page":"1","article-title":"Publication 103, Recommendations of the International Commission on Radiological Protection","volume":"37","author":"International Commission on Radiological Protection","year":"2007","journal-title":"Ann ICRP"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0030","volume":"48","year":"2019","journal-title":"Ann ICRP"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14736691211060117","article-title":"ICRU Report 96, Dosimetry-guided radiopharmaceutical therapy","volume":"21","author":"Sgouros","year":"2021","journal-title":"J ICRU"},{"key":"10.1016\/j.ejmp.2023.103166_b0040","unstructured":"International Atomic Energy Agency, Radiation protection and safety of radiation sources: International basic safety standards. General Safety Requirements Part 3. 2014, Vienna: International Atomic Energy Agency."},{"key":"10.1016\/j.ejmp.2023.103166_b0045","first-page":"44","article-title":"on the Community code relating to medicinal products for human use","volume":"2001","author":"Directive 2001\/83\/EC of the European Parliament and of the Council of 6","year":"2001","journal-title":"Off J Eur Communities"},{"key":"10.1016\/j.ejmp.2023.103166_b0050","first-page":"66","article-title":"on medical devices, amending Directive 2001\/83\/EC, Regulation (EC) No 178\/2002 and Regulation (EC) No 1223\/2009 and repealing Council Directives 90\/385\/EEC and 93\/42\/EEC","volume":"2017","author":"Regulation (EU) 2017\/745 of the european parliament and of the council of 5","year":"2017","journal-title":"Off J Eur Union"},{"issue":"17","key":"10.1016\/j.ejmp.2023.103166_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27175429","article-title":"Radionuclides for Targeted Therapy: Physical Properties","volume":"27","author":"Stokke","year":"2022","journal-title":"Molecules"},{"issue":"1126","key":"10.1016\/j.ejmp.2023.103166_b0060","doi-asserted-by":"crossref","first-page":"20210547","DOI":"10.1259\/bjr.20210547","article-title":"The internal dosimetry user group position statement on molecular radiotherapy","volume":"94","author":"Gear","year":"2021","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40658-017-0194-3","article-title":"Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force","volume":"4","author":"Stokke","year":"2017","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40658-017-0193-4","article-title":"Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey","volume":"4","author":"Sjogreen Gleisner","year":"2017","journal-title":"EJNMMI Phys"},{"issue":"2","key":"10.1016\/j.ejmp.2023.103166_b0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejmp.2023.103166_b0080","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejmp.2023.103166_b0085","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sjogreen Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2023.103166_b0090","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to (90)Y- and (177)Lu-PRRT provides the basis for optimization through individualized treatment planning","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ejmp.2023.103166_b0095","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00259-009-1261-3","article-title":"A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer","volume":"37","author":"Flux","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.ejmp.2023.103166_b0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2967\/jnumed.121.262069","article-title":"Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE","volume":"63","author":"Roth","year":"2022","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.ejmp.2023.103166_b0105","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1089\/thy.2021.0302","article-title":"A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease","volume":"31","author":"Taprogge","year":"2021","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.ejmp.2023.103166_b0110","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-014-2824-5","article-title":"The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy","volume":"41","author":"Strigari","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.ejmp.2023.103166_b0115","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with (90)Y in the SARAH Study","volume":"296","author":"Hermann","year":"2020","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejmp.2023.103166_b0125","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-018-4136-7","article-title":"EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations","author":"Gear","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2023.103166_b0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmp.2021.11.001","article-title":"Overview of commercial treatment planning systems for targeted radionuclide therapy","volume":"92","author":"Della Gala","year":"2021","journal-title":"Phys Med"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40658-021-00394-3","article-title":"EANM dosimetry committee series on standard operational procedures: a unified methodology for (99m)Tc-MAA pre- and (90)Y peri-therapy dosimetry in liver radioembolization with (90)Y microspheres","volume":"8","author":"Chiesa","year":"2021","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40658-020-0282-7","article-title":"EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours","volume":"7","author":"Gear","year":"2020","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.ejmp.2023.103166_b0145","series-title":"EANM Dosimetry Committee Series on Standard Operational Procedures for Pre-Therapeutic Dosimetry II","author":"Hanscheid","year":"2013"},{"key":"10.1016\/j.ejmp.2023.103166_b0150","doi-asserted-by":"crossref","unstructured":"Chiesa, C., et al., Dosimetric optimization of nuclear medicine therapy based on the Council Directive 2013\/59\/EURATOM and the Italian law N. 101\/2020. Position paper and recommendations by the Italian National Associations of Medical Physics (AIFM) and Nuclear Medicine (AIMN). Phys Med, 2021. 89: p. 317-326.","DOI":"10.1016\/j.ejmp.2021.07.001"},{"key":"10.1016\/j.ejmp.2023.103166_b0155","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-022-05786-w","article-title":"Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients","author":"Sundlov","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1073","key":"10.1016\/j.ejmp.2023.103166_b0160","doi-asserted-by":"crossref","first-page":"20160637","DOI":"10.1259\/bjr.20160637","article-title":"SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective","volume":"90","author":"Wadsley","year":"2017","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40658-020-00332-9","article-title":"Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project","volume":"7","author":"Taprogge","year":"2020","journal-title":"EJNMMI Phys"},{"issue":"10","key":"10.1016\/j.ejmp.2023.103166_b0170","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study","volume":"49","author":"Lam","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40658-018-0213-z","article-title":"Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals","volume":"5","author":"Wevrett","year":"2018","journal-title":"EJNMMI Phys"},{"issue":"10","key":"10.1016\/j.ejmp.2023.103166_b0180","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2967\/jnumed.115.170571","article-title":"124I PET assessment of response of bone metastases to initial radioiodine treatment of differentiated thyroid cancer","volume":"57","author":"Jentzen","year":"2016","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.ejmp.2023.103166_b0185","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","article-title":"Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group","volume":"50","author":"Salem","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.ejmp.2023.103166_b0190","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2967\/jnumed.109.064469","article-title":"Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma","volume":"50","author":"Buckley","year":"2009","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.ejmp.2023.103166_b0195","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.112.107524","article-title":"Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment","volume":"54","author":"Sandstr\u00f6m","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejmp.2023.103166_b0205","first-page":"99S","article-title":"Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship","volume":"46","author":"Barone","year":"2005","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.ejmp.2023.103166_b0210","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/MNM.0000000000000826","article-title":"Dosimetry-based treatment for Graves' disease","volume":"39","author":"Hyer","year":"2018","journal-title":"Nucl Med Commun"},{"issue":"11","key":"10.1016\/j.ejmp.2023.103166_b0215","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00259-015-3068-8","article-title":"Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology","volume":"42","author":"Chiesa","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.ejmp.2023.103166_b0220","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","article-title":"Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations","volume":"51","author":"Strigari","year":"2010","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.ejmp.2023.103166_b0225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40658-021-00397-0","article-title":"A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT\/CT imaging performed within the MRTDosimetry project","volume":"8","author":"Tran-Gia","year":"2021","journal-title":"EJNMMI Phys"},{"issue":"3","key":"10.1016\/j.ejmp.2023.103166_b0230","doi-asserted-by":"crossref","first-page":"271","DOI":"10.23736\/S1824-4785.19.03202-3","article-title":"Physics aspects of setting up a multicenter clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer","volume":"63","author":"Taprogge","year":"2019","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ejmp.2023.103166_b0235","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clon.2020.11.008","article-title":"Multicentre Trials on Standardised Quantitative Imaging and Dosimetry for Radionuclide Therapies","volume":"33","author":"Lassmann","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ejmp.2023.103166_b0240","volume":"no 174","author":"Commission","year":"2014"},{"key":"10.1016\/j.ejmp.2023.103166_b0245","series-title":"International Atomic Energy Agency, A model to assess staffing needs in nuclear medicine, in IAEA Human health reports","author":"Iaea","year":"2022"},{"issue":"1135","key":"10.1016\/j.ejmp.2023.103166_b0250","doi-asserted-by":"crossref","first-page":"20211393","DOI":"10.1259\/bjr.20211393","article-title":"Guidance on medical physics expert support for nuclear medicine","volume":"95","author":"Fraser","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ejmp.2023.103166_b0255","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/jama.1946.02870490016004","article-title":"Radioactive iodine therapy: Effect on functioning metastases of adenocarcinoma of the thyroid","volume":"132","author":"Seidlin","year":"1946","journal-title":"J Am Med Assoc"}],"container-title":["Physica Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S112017972300193X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S112017972300193X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:57:00Z","timestamp":1761105420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S112017972300193X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":51,"alternative-id":["S112017972300193X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmp.2023.103166","relation":{},"ISSN":["1120-1797"],"issn-type":[{"value":"1120-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy \u2013 Molecular radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Physica Medica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmp.2023.103166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Associazione Italiana di Fisica Medica e Sanitaria. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103166"}}